Selected Start-Ups (09/00)
Executive SummaryIn Vivo summarizes the technologies of several recently founded companies: Ardana Bioscience Ltd., spun-out in July from Britain's Medical Research Council, will commercialize research related to contraception and women's health. DiscoveRx will use proprietary enzyme fragment technology originally developed for clinical assays for SNP detection, to identify and validate drug targets, screen for drug leads, and collect pharmakinetic data on drugs in development. Fluorous Technologies Inc. was formed in June to commercialize fluorous organic chemistry technology developed by University of Pittsburgh chemistry professor Dennis P. Curran, PhD. Created by the founders of Geneva Bioinformatics Inc., Geneva Proteomics Inc. will obtain proteomic data by analyzing biologic fluids and tissues in health and sick individuals, enhance the data through bioinformatics, and sell information and synthesized proteins to clients. Hyalose LLC will commercialize unique recombinant technology developed by Paul H. Weigel, PhD and Paul L. DeAngelis, PhD at the University of Oklahoma Health Sciences Center (OUHSC) for the production of designer hyaluronan and novel polysaccharides. CMEA, Bay City, MPM and Versant are backing Syrrx Inc., a new entrant in the structural genomics field.
You may also be interested in...
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
A year into his role as a CEO of the Belgian mRNA biotech eTheRNA immunotherapies, industry veteran Steven Powell talks to In Vivo about his plans for the business over the coming couple of years. An important timeframe to move the company well into clinical activity.